Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Ferroptosis as a target mechanism in heart and kidney disease
Simar J. Singh, Baljash Cheema, Hossein Ardehali
Simar J. Singh, Baljash Cheema, Hossein Ardehali
View: Text | PDF
Review

Ferroptosis as a target mechanism in heart and kidney disease

  • Text
  • PDF
Abstract

Ferroptosis is a distinct form of regulated cell death driven by lipid peroxidation and redox imbalance. Since its formal recognition in 2012, ferroptosis has emerged as a central pathway linking metabolic stress and oxidative injury to both physiologic and pathologic processes. Its functions extend from tissue sculpting during embryogenesis and tumor suppression to pathologic contributions in neurodegeneration, cardiovascular disease, liver and kidney injury, cancer, and inflammatory disorders. Despite these advances in our understanding of ferroptosis, critical questions remain regarding its precise regulation, context-specific consequences, and interactions with other cell death pathways. Continued progress in identifying biomarkers, defining context-specific roles, and developing selective modulators will be essential to translate ferroptosis biology into clinical therapies with broad impact. Here, we describe the current state of our understanding of the role of ferroptosis in physiology and its potential as a target mechanism in heart and kidney disease.

Authors

Simar J. Singh, Baljash Cheema, Hossein Ardehali

×

Figure 1

Ferroptosis propagation and inhibition.

Options: View larger image (or click on image) Download as PowerPoint
Ferroptosis propagation and inhibition.
Ferroptosis is a form of regulat...
Ferroptosis is a form of regulated cell death caused by overwhelming lipid peroxidation. The Fenton reaction converts cytosolic hydrogen peroxide or membrane-residing lipid hydroperoxide (L-OOH) into highly reactive hydroxyl radicals, which initiate lipid peroxidation. Alternatively, PUFAs incorporated into the membrane undergo oxidation, resulting in the formation of L-OOH. Multiple mechanisms modulate or inhibit ferroptosis. System Xc− imports cystine into the cell, which is reduced to cysteine, the rate-limiting precursor for GSH synthesis. Alternatively, methionine may be used to generate cysteine via the methionine cycle and TSS pathway. GPX4 uses GSH to reduce L-OOH to nontoxic lipid alcohols, thereby protecting cellular membranes from oxidative damage. Other antioxidant defense systems, such as the FSP1-CoQ10 system and BH4/BH2, independently suppress ROS accumulation and inhibit ferroptosis. IKE, imidazole ketone erastin; PUFA-PL, polyunsaturated fatty acid phospholipid; TSS, transulfuration; FSP1, ferroptosis suppressor protein 1; BH4/BH2, tetrahydrobiopterin/dihydrobiopterin; HMG-CoA; 3-hydroxy-3-methylglutaryl-coenzyme A; Ac-CoA; acetyl CoA.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts